Stock of the Day

Merus (MRUS)

$57.08

+$1.07 (+1.9%)

Market Cap: $3.90B

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Recent News

• Why Merus N.V. (MRUS) Crashed On Wednesday (msn.com)
• Merus Shares Slide on Stock Offering (marketwatch.com)
• Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares (quiverquant.com)
• Merus N.V. Announces Pricing of Public Offering of Common Shares (globenewswire.com)
• Merus NV Announces Proposed Public Offering of Common Shares | MRUS stock news (gurufocus.com)
• Merus N.V. Announces Proposed Public Offering of Common Shares (globenewswire.com)